MC 510027

Drug Profile

MC 510027

Alternative Names: Milbemycin alpha-9

Latest Information Update: 04 Oct 2004

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical; Essential Therapeutics [CEASED]
  • Class Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 04 Oct 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
  • 04 Oct 2004 Discontinued - Preclinical for Mycoses in Japan (unspecified route)
  • 26 May 2003 No development reported - Preclinical for Mycoses in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top